Investigating parametric digital PET imaging in theranostic. Application to personalized 177Lu-based cancer treatments
Recrutement: 
Recrutement en cours/passé: 
Recrutement passé
Periode: 
2021
Contact: 
Supervisors: David Sarrut (david.sarrut@creatis.insa-lyon.fr) and Jean-Noël Badel (jeannoel.badel@lyon.unicancer.fr)

This work is a collaboration between CREATIS lab, LUMEN[1] and Siemens Healthineers. The PhD will be located in Lyon, France. It will be funded by a CIFRE contract (see ANRT). The goal is to investigate the interest of parametric PET images in predicting patient personalized dosimetry of 177Lu-based cancer treatments usually obtained from multiple SPECT images in order to improve and simplify the theranostic workflow.

Medical context

Personalized 177Lu-based therapy is rapidly expanding in the nuclear medicine field. It consists in intravenous administration of a molecular vector radiolabeled with 177Lu. The molecular vector allows the absorption of β-emitting 177Lu in the target organs, which leads to cytotoxic effects. One typical example is the treatment of neuroendocrine tumors when surgery is not indicated [1]. 177Lu-based therapy treatment planning is based on a theranostic approach which consists in several steps.

First, a pre-treatment PET imaging is acquired to evaluate the biological targets in patients before starting their treatment. The standard approach for this step is composed of conventional static PET images acquired usually 60 minutes post injection of 68Ga labeled tracer.

Second, after this first planning phase, the treatment itself is administrated by 177Lu injection. Ideally, several SPECT images are acquired, e.g. 4h, 24h and 96h post-injection, in order to obtain information about the biodistribution and the pharmacokinetic of the radiolabeled molecule. These information are the basis for deriving personalized dosimetry, which is crucial to better understand treatment efficacy and predict potential toxicity. However, such per-treatment SPECT acquisitions are time consuming and difficult to manage in practice.

The conventional pre-treatment static PET images provide semi-quantitative analyses of uptake at a voxel or organ-level in the target volumes but not a true quantification of patient metabolism nor a thorough dynamic physiological processes, also named parametric information [2, 3]. This parametric information is expected to be superior to the information obtained by conventional static PET imaging and holds great potential in a theranostic approach. However, the limited axial field of view and the lack of user-friendly clinical software for data analysis have limited the dynamic acquisitions implementation into clinical routine [4,5].

The recent development of SiPM-based PET, or so-called “digital PET”, offers better spatial and temporal resolutions and sensitivity and is likely to improve dynamic PET acquisition quality to reconstruct maps of kinetic parameters related to the metabolism of the injected tracer.

In this context, we propose to investigate the interest of parametric digital PET imaging in a theranostic approach for 177Lu-based treatments. Ideally, correlation between parametric PET and per-treatment SPECT images and associated dosimetry will be studied in order to derive recommendations.

Database

We will focus on 177Lu-PSMA treatments, an innovative treatment for metastatic castration-resistant prostate cancer that uses 177Lu conjugated to ligand PSMA-617. Prostate-specific membrane antigen (PSMA) is a cell membrane glycoprotein that is selectively expressed in prostate cells, with high expression levels in prostatic adenocarcinoma. In a clinical study starting in our department, patients will have both pre-treatment 68Ga parametric PET images and several per-treatment 177Lu SPECT acquisition allowing complete personalized dosimetry. It is however expected that, in future studies, the number of SPECT acquisitions will be reduced due to time and clinical constraints. This database will thus be one of this kind allowing to investigate PET and SPECT dosimetry information relationship.

Objectives

1) First, optimize the dynamic acquisition parameters for the Siemens Digital Biograph Vision 450 PET/CT. In particular, investigate the acquisition protocol to obtain 68Ga image over a large patient field of view, corresponding to the one of the subsequent SPECT image. To that end, experimental measurements will have to be performed. The parameters obtained will be implemented in a clinical practice at LUMEN nuclear medicine department.

2) Investigate correlation between parametric PET images and 177Lu-treatment dosimetry based on per-treatment SPECT images. This work will be carried out in collaboration with a parallel study on dosimetry 177Lu underway in our research team.

Keywords

Theranostic, parametric PET imaging, digital PET, personalized radionuclide therapy

Environment

The recruited PhD student will work in a multidisciplinary team composed of nuclear physicians, medical physicists, radiopharmacists, researchers and computer scientists of CREATIS laboratory, Leon-Bérard and HCL cancer centers. This study will give the student the opportunity to work in both imaging and dosimetry in the field of nuclear medicine.

Recommended skills

  • Education: master in medical physics, applied mathematics or image processing.
  • Scientific interests: medical physics, applied mathematics, computer sciences (medical image processing), x-ray and nuclear physics and imaging.
  • Programming skills: Python highly recommended
  • Languages: English required, French optional.

Practical information

How to apply?

Send CV + covering letter outlining your motivation + grades in master. If possible: recommendation letters from previous supervisors or teachers.

References

[1] M. Del Prete et al., “Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial,” Eur. J. Nucl. Med. Mol. Imaging, vol. 46, no. 3, pp. 728–742, 2019, doi: 10.1007/s00259-018-4209-7.

[2] RP. Baum et al., “THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – The bad Berka experience” Theranostics, 2012;2(5):437-447.

[3] A. Yordanova et al., “Theranostic in nuclear medicine practice” OncoTargets and Therapy, 2017;4821-4828.

[4] Dimitrakopoulou-Strauss et al. “Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives” EJNMMI 2020 May https://link.springer.com/article/10.1007/s00259-020-04843-6

[5] Herrmann et al., “Radiotheranostics: a roadmap for future development”, Lancet Oncol. 2020 March ; 21(3): e146–e156. doi:10.1016/S1470-2045(19)30821-6.


[1] joint nuclear medicine department of Léon-Bérard comprehensive cancer center and Hospices Civils de Lyon